Transgene 将来の成長

Future 基準チェック /06

Transgeneの収益は年間34.8%で減少すると予測されていますが、年間収益は年間2.9%で増加すると予想されています。EPS は年間35%で減少すると予想されています。

主要情報

-34.8%

収益成長率

-35.0%

EPS成長率

Biotechs 収益成長	5.4%
収益成長率	2.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Oct 2024

今後の成長に関する最新情報

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19

Recent updates

Is Transgene (EPA:TNG) Using Too Much Debt?

Jun 15

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Mar 21

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Jan 23

業績と収益の成長予測

ENXTPA:TNG - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	12	-56	-62	-61	1
12/31/2025	17	-47	-54	-52	1
12/31/2024	22	-30	-40	-38	1
6/30/2024	6	-23	-39	-36	N/A
3/31/2024	7	-23	-38	-35	N/A
12/31/2023	8	-22	-37	-35	N/A
9/30/2023	8	-28	-36	-34	N/A
6/30/2023	9	-33	-35	-33	N/A
3/31/2023	10	-33	-28	-26	N/A
12/31/2022	10	-33	-22	-20	N/A
9/30/2022	14	-28	-18	-17	N/A
6/30/2022	18	-23	-15	-15	N/A
3/31/2022	18	-21	-21	-20	N/A
12/31/2021	17	-20	-27	-26	N/A
9/30/2021	13	-23	-29	-28	N/A
6/30/2021	9	-27	-31	-30	N/A
3/31/2021	9	-22	-30	-29	N/A
12/31/2020	10	-17	-30	-29	N/A
9/30/2020	12	-11	-31	-30	N/A
6/30/2020	14	-6	-33	-31	N/A
3/31/2020	14	-12	-28	-27	N/A
12/31/2019	13	-19	-24	-22	N/A
9/30/2019	11	-6	-24	-23	N/A
6/30/2019	8	8	-23	-23	N/A
3/31/2019	8	8	-26	-25	N/A
12/31/2018	7	8	-29	-28	N/A
9/30/2018	7	-10	-31	-29	N/A
6/30/2018	7	-29	-32	-30	N/A
3/31/2018	7	-31	N/A	-33	N/A
12/31/2017	7	-32	N/A	-35	N/A
9/30/2017	8	-32	N/A	-36	N/A
6/30/2017	9	-31	N/A	-37	N/A
3/31/2017	9	-28	N/A	-35	N/A
12/31/2016	10	-24	N/A	-34	N/A
9/30/2016	10	-26	N/A	-37	N/A
6/30/2016	9	-28	N/A	-40	N/A
3/31/2016	9	-33	N/A	-43	N/A
12/31/2015	10	-38	N/A	-45	N/A
9/30/2015	10	-40	N/A	-48	N/A
6/30/2015	10	-42	N/A	-50	N/A
3/31/2015	11	-41	N/A	-52	N/A
12/31/2014	11	-41	N/A	-54	N/A
9/30/2014	13	-41	N/A	-52	N/A
6/30/2014	15	-41	N/A	-50	N/A
3/31/2014	15	-42	N/A	-50	N/A
12/31/2013	16	-43	N/A	-50	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TNG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TNG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TNG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TNGの収益 ( 2.9% ) French市場 ( 5.5% ) よりも低い成長が予測されています。

高い収益成長: TNGの収益 ( 2.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TNGの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/22 08:45
終値	2024/12/20 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Transgene SA 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。11

アナリスト	機関
Olga Smolentseva	Bryan Garnier & Co
Brandon Folkes	Cantor Fitzgerald & Co.
Arsene Guekam	CIC Market Solutions (ESN)

Transgene 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 45%

Price target decreased by 11% to €3.50

Consensus revenue estimates fall by 23%

Price target decreased by 7.6% to €3.67

Consensus revenue estimates fall by 15%

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

New minor risk - Market cap size

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023)

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

Consensus revenue estimates fall by 45%

Is Transgene (EPA:TNG) Using Too Much Debt?

New major risk - Financial position

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

Price target decreased by 11% to €3.50

New major risk - Financial position

Consensus revenue estimates fall by 23%

Price target decreased by 7.6% to €3.67

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Consensus revenue estimates fall by 15%

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released: EPS: €0 (vs €0.14 loss in 1H 2021)

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Consensus forecasts updated

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

Consensus forecasts updated

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day high: €2.70

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.77

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes